ClinicalTrials.gg
CompletedNCT03278080Updated Feb 28, 2025

Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1

An interventional study of Road-tracking test and Car-following test in Healthy Participants, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 21 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Taisho Pharmaceutical Co., Ltd. · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
21 Years to 64 Years
Sex
Male
01

Study summary

The purpose of this study is to set an optimal measurement time for assessing driving ability in a driving simulator in healthy volunteers.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥18.5 and \<25.0 kg/m2 at screening inspection
  • No visual impairment (enable to correct the vision with eyeglasses or contact lens)
  • Receive a prior explanation on the study, able to accept its content, and capable to provide voluntary written consent for participation in this study

Exclusion criteria

Exclusion Criteria:

  • History of drug and food allergy
  • Routinely drink alcohol before bedtime
  • Inappropriate for enrollment in this study was judged by principal investigator or subinvestigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    driving test

    Other: Road-tracking test · Other: Car-following test · Other: Harsh-braking test

Interventions

  • OtherRoad-tracking test

    Driving with simulator program for SDLP measurement

  • OtherCar-following test

    Driving with simulator program for DCV measurement

  • OtherHarsh-braking test

    Driving with simulator program for BRT measurement

06

What researchers measure

Primary outcomes

  1. Standard Deviation of Lateral Position (SDLP)

    Time frame: 60 min.

Secondary outcomes

  1. Distance Coefficient of Variation (DCV)

    Time frame: 25 min.

  2. Brake Reaction Time (BRT)

    Time frame: 15 min.

07

Study locations

1 site
  • Taisho Pharmaceutical Co., Ltd selected site
    Fukuoka, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Oct 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2017
First posted
Sep 11, 2017
StartActual
Sep 22, 2017
Primary completionActual
Oct 25, 2017
CompletionActual
Oct 25, 2017
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03278080
Collaborators
Nagoya University
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Sep 22, 2017
Primary completion
Oct 25, 2017
Completion
Oct 25, 2017
Last update
Feb 28, 2025

Study contacts

Shigeru Okuyama
study director · Taisho Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion